Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20915394 | 0.87 | CA2 (0.46) | SMN1; SMN2CA2 | |
| SCHEMBL3846515 | 0.78 | LMNA (0.44) | LMNAALDH1A1SMN1; SMN2HTTKMT2A | |
| SCHEMBL11110817 | 0.76 | ALDH1A1 (0.50) | LMNAALDH1A1SMN1; SMN2HTTKMT2A | |
| SCHEMBL7856535 | 0.76 | CA2 (0.62) | LMNAALDH1A1SMN1; SMN2HTTCA2 | |
| SCHEMBL12040860 | 0.76 | CA2 (0.62) | LMNAALDH1A1SMN1; SMN2HTTCA2 | |
| SCHEMBL8337020 | 0.74 | CA2 (0.60) | LMNAALDH1A1SMN1; SMN2HTTCA2 | |
| SCHEMBL11800668 | 0.74 | TDP1 (0.56) | LMNAALDH1A1SMN1; SMN2HTTTDP1 | |
| SCHEMBL4482607 | 0.74 | LMNA (0.60) | LMNAALDH1A1SMN1; SMN2HTTCA2 | |
| SCHEMBL9157917 | 0.72 | HPGD (0.40) | ALDH1A1HTTKMT2ATDP1CNR2 | |
| SCHEMBL19212523 | 0.72 | LMNA (0.42) | LMNAALDH1A1SMN1; SMN2HTTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153642-B | Indole and azaindole halogenated allylamine derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-10717734-B2 | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof | PHARMAXIS LTD. (AU) | 2020-07-21 | — | — | US | disclosed |
| US-20190119269-A1 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717734-B2 | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof | IDO1, IDO2, INMT | LMNA 1651/4885ALDH1A1 322/4885SMN1; SMN2 4655/4885 |
| US-20190119269-A1 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | IDO1, IDO2, INMT | LMNA 1651/4885ALDH1A1 322/4885SMN1; SMN2 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.